Reviews
PSMA-Targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer
Del Re et alDrugs

Metastatic castration-resistant prostate cancer (mCRPC) presents substantial clinical challenges due to hormonal therapy resistance and poor survival outcomes despite systemic interventions. Radioligand therapy targeting prostate-specific membrane antigen (PSMA) has emerged as an effective therapeutic strategy. PSMA is a transmembrane glycoprotein with high expression in prostate cancer cells and minimal distribution in normal tissues, providing selective targeting that minimises toxicity.
The radiotheranostic agent [177Lu]Lu-PSMA-617 couples the small molecule ligand PSMA-617 with the beta-emitting radioisotope 177 Lutetium. In patients with mCRPC who have progressed following androgen receptor pathway inhibitors and taxane-based chemotherapy, this therapy has demonstrated efficacy, leading to regulatory approval in the USA, UK, and Europe. Key clinical trials, including TheraP, VISION, and PSMAfore, have established the clinical role of [177Lu]Lu-PSMA-617.
From a practical pharmacotherapeutic perspective, [177Lu]Lu-PSMA-617 has no relevant drug–drug interaction risk, enabling safe consideration in combination with other anti-tumour agents—an important benefit for frail patients managing polypharmacy. Current research focuses on strategies to enhance PSMA expression to improve therapeutic response, exploring potential additive effects with other therapies, and addressing post-treatment management to optimise long-term patient outcomes.
Key Takeaways
- [177Lu]Lu-PSMA-617 has demonstrated efficacy in patients with metastatic castration-resistant prostate cancer who have progressed after androgen receptor pathway inhibitors and taxane-based chemotherapy, securing regulatory approval in the USA, UK, and Europe.
- The radioligand carries no relevant drug–drug interaction risk, allowing it to be safely considered for combination regimens in frail patients with mCRPC managed with polypharmacy.
